SUDARSHAN PHARMA INDUSTRIES LTD

Head Office: 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/57 Date: 5th September 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Intimation for approval to acquire share capital of M/s. MedTherapy Biotechnology Inc., USA
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 (‘**SEBI Listing Regulations**’), this is to inform you that the Board of Directors of the Company have at their meeting held on 5th September 2026, inter-alia, approved to acquire 24,23,675.64 equity shares of Common Stock, par value US$0.0001 per share of MedTherapy Biotechnology Inc., a corporation incorporated under the laws of the State of Delaware, equivalent to 9.50% of the issued and outstanding share capital of the Company.

Mr. Hemal Mehta (Chairman & Managing Director) and Mr. Sachin Mehta (Joint Managing Director), Promoters of the Company, shall acquire 3,82,685.63 equity shares of Common Stock, par value US$0.0001 per share of MedTherapy Biotechnology Inc., equivalent to 1.50% each of the issued and outstanding share capital of the Company.

The relevant Legal and commercial DD will be concluded before closure of the transaction and all the relevant FEMA regulations will be addressed for the transaction.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given in Annexure-A.

The meeting of the Board of Directors commenced at 4.30 pm and concluded at 5.00 pm.

You are requested to take the same on record.

Thanks & Regards,
Yours faithfully,

For, **Sudarshan Pharma Industries Limited**

SACHIN VASANTRAI MEHTA
Digitally signed by SACHIN VASANTRAI MEHTA Date: 2026.09.05 19:24:47 +05'30'

Sachin Mehta
Joint Managing Director

SUDARSHAN PHARMA INDUSTRIES LTD

Head Office: 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

Annexure - A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

Sr. No.	Details to be provided	Information
1	Name of the target entity, details in brief such as size, etc.	**Name:** MedTherapy Biotechnology Inc., a corporation incorporated under the laws of the State of Delaware, USA M/s. MedTheraphy Biotechnology Inc ("**MedTherapy Biotech**") is Boston based global Cancer Cell & Gene Therapy Company founded in 2018 by experts from Harvard and former Novartis executives as an end-to-end, integrated CAR-T Cell CDMO, with commercial scale GMP manufacturing facility in New Delhi, India and technology development site at Boston, USA.
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	MedTherapy Biotech was founded by experts in the cancer field with a mission to make this treatment so affordable and accessible that almost every cancer patient would be able to afford it.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Objects of acquiring 9.50% common stock of MedTherapy Biotech includes: i. Enter the U.S. market and establish a presence there. ii. Access the customer base, contracts, distribution network. iii. Expand into new products and services.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route).
6	Indicative time period for completion of the acquisition	31st March 2027

SACHIN VASANTRAI MEHTA
Digitally signed by SACHIN VASANTRAI MEHTA
Date: 2026.09.05 19:25:15 +05'30'

7	Nature of Consideration whether Cash consideration or share swap and details of the same	Consideration to be paid in cash in US Dollars.
8	Cost of acquisition or the price at which the shares are acquired.	Cost of acquisition is based upon valuation of MedTherapy Biotechnology as per prevailing valuation norms.
9	Percentage of shareholding control acquired and /or number of shares acquired	24,23,675.64 equity shares of Common Stock, par value US$0.0001 per share of MedTherapy Biotechnology Inc., a corporation incorporated under the laws of the State of Delaware, equivalent to 9.50% of the issued and outstanding share capital of the Company. Mr. Hemal Mehta (Chairman & Managing Director) and Mr. Sachin Mehta (Joint Managing Director), Promoters of the Company, shall acquire 3,82,685.63 equity shares of Common Stock, par value US$0.0001 per share of MedTherapy Biotechnology, equivalent to 1.50% each of the issued and outstanding share capital of the Company.
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<u>Brief background:</u> MedTheraphy Biotechnology is Boston based global Cancer Cell & Gene Therapy Company founded in 2018 by experts from Harvard and former Novartis executives as an end-to-end, integrated CAR-T Cell CDMO, with commercial scale GMP manufacturing facility in New Delhi, India and technology development site at Boston, USA. MedTherapy Biotech was founded by experts in the cancer field with a mission to make this treatment so affordable and accessible that almost every cancer patient would be able to afford it.

For, **Sudarshan Pharma Industries Limited**

SACHIN VASANTRAI MEHTA
Digitally signed by SACHIN VASANTRAI MEHTA
Date: 2026.09.05 19:25:33 +05'30'

Sachin Mehta
Joint Managing Director